The US Department of Health and Human Services said it will require that all new vaccines be tested in placebo-controlled ...

The potential change outlined in a statement would require all new vaccines to undergo placebo testing, sparking concerns ...

Dr. Marty Makary, chief of the FDA, has expressed doubts about the agency approving the COVID-19 vaccine for winter, stating ...

Novavax's protein-only vaccine is once again expected to move from emergency approval to full approval status following a pause.

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Usha Lee McFarling ...

Here are eight possible indicators of how health secretary Robert F. Kennedy Jr. may handle U.S. vaccine policy in coming ...

Novavax Inc. closed 73.09% below its 52-week high of $23.86, which the company achieved on June 6th.

The unusual move at FDA comes shortly after the agency's longtime vaccine chief was forced out over disagreements with Makary ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

(Reuters) -Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services Secretary Robert F. Kennedy Jr. raised concerns about the company's COVID-19 ...